Stock INTEG B INTEGRUM AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Integrum AB

Equities

INTEG B

SE0009807266

Delayed Nasdaq Stockholm
Other stock markets
 06:51:20 2024-05-15 am EDT 		5-day change 1st Jan Change
56.4 SEK +2.55% Intraday chart for Integrum AB +8.91% +23.11%
May. 02 Integrum Expands Its Product Offering to the United Kingdom Market CI
Mar. 26 Integrum Enters a Commercial agreement with AMI Technologies to introduce the OPRATM Implant System in Israel CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • With an expected P/E ratio at 1375 and 73.66 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
INTEGRUM AB Stock Integrum AB
+23.11% 93.71M -
STRAUMANN HOLDING AG Stock Straumann Holding AG
-11.14% 21.11B
B
SONOVA HOLDING AG Stock Sonova Holding AG
+6.23% 18.8B
A
COCHLEAR LIMITED Stock Cochlear Limited
+11.12% 14.12B
B
DEMANT A/S Stock Demant A/S
+9.05% 10.2B
B-
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD. Stock Eyebright Medical Technology (Beijing) Co., Ltd.
-11.30% 2.22B -
EMBLA MEDICAL HF. Stock Embla Medical hf.
+7.10% 1.78B
B+
ANGELALIGN TECHNOLOGY INC. Stock Angelalign Technology Inc.
+34.04% 1.64B
D-
MODERN DENTAL GROUP LIMITED Stock Modern Dental Group Limited
+24.42% 648M -
ANGEL ROBOTICS CO., LTD. Stock Angel Robotics Co., Ltd.
0.00% 394M - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. INTEG B Stock
  4. Ratings Integrum AB
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW